By Marc Hurlbert, PhD | CEO
The Melanoma Research Alliance (MRA) and our collaborators at the Veterans Administration (VA) Hospitals in Boston and Providence, and at Massachusetts General Hospital (MGH), have finalized our veteran and civilian cohorts. We have jointly assembled the largest, retrospective cohorts of three rare melanoma subtypes: >1800 patients with acral, >600 mucosal, and >2200 uveal melanoma cases. We have submitted three manuscripts for consideration for publication to peer-reviewed scientific journals including the acral veterans’ analysis, acral civilian cohort analysis, and an unplanned analysis of “acral” by anatomic location on the body. The team has also finished our first pass analysis of clinical and sociological risk factors for uveal and mucosal melanoma. Over the next 90 day we are sequencing germline DNA from available cases to understand if there are any heritable risk factors for rare melanomas. We aim to complete this project by late Fall 2025.
Project reports on GlobalGiving are posted directly to globalgiving.org by Project Leaders as they are completed, generally every 3-4 months. To protect the integrity of these documents, GlobalGiving does not alter them; therefore you may find some language or formatting issues.
If you donate to this project or have donated to this project, you can receive an email when this project posts a report. You can also subscribe for reports without donating.
Support this important cause by creating a personalized fundraising page.
Start a Fundraiser
